| Literature DB >> 24719451 |
Philipp Mertins1, Feng Yang2, Tao Liu2, D R Mani3, Vladislav A Petyuk2, Michael A Gillette3, Karl R Clauser3, Jana W Qiao3, Marina A Gritsenko2, Ronald J Moore2, Douglas A Levine4, Reid Townsend5, Petra Erdmann-Gilmore5, Jacqueline E Snider5, Sherri R Davies5, Kelly V Ruggles6, David Fenyo6, R Thomas Kitchens5, Shunqiang Li5, Narciso Olvera4, Fanny Dao4, Henry Rodriguez7, Daniel W Chan8, Daniel Liebler9, Forest White10, Karin D Rodland2, Gordon B Mills11, Richard D Smith2, Amanda G Paulovich12, Matthew Ellis5, Steven A Carr1.
Abstract
Protein abundance and phosphorylation convey important information about pathway activity and molecular pathophysiology in diseases including cancer, providing biological insight, informing drug and diagnostic development, and guiding therapeutic intervention. Analyzed tissues are usually collected without tight regulation or documentation of ischemic time. To evaluate the impact of ischemia, we collected human ovarian tumor and breast cancer xenograft tissue without vascular interruption and performed quantitative proteomics and phosphoproteomics after defined ischemic intervals. Although the global expressed proteome and most of the >25,000 quantified phosphosites were unchanged after 60 min, rapid phosphorylation changes were observed in up to 24% of the phosphoproteome, representing activation of critical cancer pathways related to stress response, transcriptional regulation, and cell death. Both pan-tumor and tissue-specific changes were observed. The demonstrated impact of pre-analytical tissue ischemia on tumor biology mandates caution in interpreting stress-pathway activation in such samples and motivates reexamination of collection protocols for phosphoprotein analysis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24719451 PMCID: PMC4083109 DOI: 10.1074/mcp.M113.036392
Source DB: PubMed Journal: Mol Cell Proteomics ISSN: 1535-9476 Impact factor: 5.911